3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
5
Phase 2
4
Phase 1
4
Phase 4
2
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
28
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasms
3
Neoplasm Metastasis
3
Prostatic Neoplasms, Castration-Resistant
2
Prostate Cancer Metastatic
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Recurrence
1
Prostatic Diseases
1
Patient Preference
1
Metastatic Castration-resistent Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
MCRPC
1
Genital Diseases, Male
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
enzalutamide
2
Prednisone
2
Abiraterone Acetate
2
tasquinimod
1
sabizabulin
1
niraparib
1
darolutamide
1
atezolizumab
1
abiraterone
1
Radiosurgery
1
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Prostatic Neoplasms, Castration-Resistant
×
enzalutamide
×
Clear all
NCT03016312
2024-08-09
IMbassador250
Hoffmann-La Roche
Phase 3
Completed
759 enrolled
22 charts
NCT04844749
2024-02-05
VERACITY
Veru Inc.
Phase 3
Terminated
105 enrolled